Tucker Katherine L, Sheppard James P, Stevens Richard, Bosworth Hayden B, Bove Alfred, Bray Emma P, Earle Kenneth, George Johnson, Godwin Marshall, Green Beverly B, Hebert Paul, Hobbs F D Richard, Kantola Ilkka, Kerry Sally M, Leiva Alfonso, Magid David J, Mant Jonathan, Margolis Karen L, McKinstry Brian, McLaughlin Mary Ann, Omboni Stefano, Ogedegbe Olugbenga, Parati Gianfranco, Qamar Nashat, Tabaei Bahman P, Varis Juha, Verberk Willem J, Wakefield Bonnie J, McManus Richard J
Nuffield Department of Primary Care, University of Oxford, Oxford, United Kingdom.
Center for Health Services Research in Primary Care, Durham VAMC, Durham, North Carolina, United States of America.
PLoS Med. 2017 Sep 19;14(9):e1002389. doi: 10.1371/journal.pmed.1002389. eCollection 2017 Sep.
Self-monitoring of blood pressure (BP) appears to reduce BP in hypertension but important questions remain regarding effective implementation and which groups may benefit most. This individual patient data (IPD) meta-analysis was performed to better understand the effectiveness of BP self-monitoring to lower BP and control hypertension.
Medline, Embase, and the Cochrane Library were searched for randomised trials comparing self-monitoring to no self-monitoring in hypertensive patients (June 2016). Two reviewers independently assessed articles for eligibility and the authors of eligible trials were approached requesting IPD. Of 2,846 articles in the initial search, 36 were eligible. IPD were provided from 25 trials, including 1 unpublished study. Data for the primary outcomes-change in mean clinic or ambulatory BP and proportion controlled below target at 12 months-were available from 15/19 possible studies (7,138/8,292 [86%] of randomised participants). Overall, self-monitoring was associated with reduced clinic systolic blood pressure (sBP) compared to usual care at 12 months (-3.2 mmHg, [95% CI -4.9, -1.6 mmHg]). However, this effect was strongly influenced by the intensity of co-intervention ranging from no effect with self-monitoring alone (-1.0 mmHg [-3.3, 1.2]), to a 6.1 mmHg (-9.0, -3.2) reduction when monitoring was combined with intensive support. Self-monitoring was most effective in those with fewer antihypertensive medications and higher baseline sBP up to 170 mmHg. No differences in efficacy were seen by sex or by most comorbidities. Ambulatory BP data at 12 months were available from 4 trials (1,478 patients), which assessed self-monitoring with little or no co-intervention. There was no association between self-monitoring and either lower clinic or ambulatory sBP in this group (clinic -0.2 mmHg [-2.2, 1.8]; ambulatory 1.1 mmHg [-0.3, 2.5]). Results for diastolic blood pressure (dBP) were similar. The main limitation of this work was that significant heterogeneity remained. This was at least in part due to different inclusion criteria, self-monitoring regimes, and target BPs in included studies.
Self-monitoring alone is not associated with lower BP or better control, but in conjunction with co-interventions (including systematic medication titration by doctors, pharmacists, or patients; education; or lifestyle counselling) leads to clinically significant BP reduction which persists for at least 12 months. The implementation of self-monitoring in hypertension should be accompanied by such co-interventions.
血压自我监测似乎可降低高血压患者的血压,但在有效实施以及哪些人群可能获益最大方面仍存在重要问题。本个体患者数据(IPD)荟萃分析旨在更好地了解血压自我监测降低血压和控制高血压的有效性。
检索了Medline、Embase和Cochrane图书馆,查找比较高血压患者自我监测与非自我监测的随机试验(2016年6月)。两名评审员独立评估文章的合格性,并联系合格试验的作者索要IPD。在初始检索的2846篇文章中,36篇符合条件。25项试验提供了IPD,包括1项未发表的研究。15/19项可能的研究(7138/8292名随机参与者,占86%)提供了主要结局的数据,即12个月时诊室或动态血压的变化以及血压控制在目标值以下的比例。总体而言,与常规护理相比,自我监测在12个月时与诊室收缩压(sBP)降低有关(-3.2 mmHg,[95%可信区间-4.9,-1.6 mmHg])。然而,这种效果受到联合干预强度的强烈影响,从单独自我监测无效果(-1.0 mmHg [-3.3,1.2])到监测与强化支持相结合时降低6.1 mmHg(-9.0,-3.2)。自我监测在服用抗高血压药物较少且基线sBP高达170 mmHg的患者中最有效。在性别或大多数合并症方面未观察到疗效差异。4项试验(1478名患者)提供了12个月时的动态血压数据,这些试验评估了几乎没有或没有联合干预的自我监测。在该组中,自我监测与较低的诊室或动态sBP均无关联(诊室-0.2 mmHg [-2.2,1.8];动态1.1 mmHg [-0.3,2.5])。舒张压(dBP)的结果相似。这项研究的主要局限性是仍存在显著的异质性。这至少部分是由于纳入标准、自我监测方案和纳入研究中的目标血压不同。
单独的自我监测与较低的血压或更好的控制无关,但与联合干预(包括医生、药剂师或患者进行系统的药物滴定;教育;或生活方式咨询)相结合可导致临床上显著的血压降低,且这种降低至少持续12个月。高血压患者自我监测的实施应伴有此类联合干预。